Merck & Co

GlaxoSmithKline

GSK's new CEO Walmsley paid 25% less than predecessor Witty

GlaxoSmithKline (GSK) has confirmed rumours that its incoming CEO Emma Walmsley will be paid less than her predecessor, Sir Andrew Witty.

News

BMS appoints new science chief in fall-out from Opdivo setba...

Bristol-Myers Squibb’s (BMS) chief scientific officer Francis Cuss is to step down following the company's huge lung cancer setback with Opdivo last year, to be replaced by former Massachus

News

Pfizer and Merck's diabetes contender looks to challenge Jar...

Merck and Pfizer have Boehringer and Lilly in their sights with ertugliflozin

News

Blow for MSD as NICE rejects Keytruda in first line lung can...

Firm will have to offer further discount to get drug to NHS patients.

News

Closeup of X-ray photography of human brain

Merck's failure casts gloom over remaining BACE Alzheimer's ...

But trial in patients in early stage of the disease continues.

News

Opdivo still clear immunotherapy leader despite Keytruda gai...

Immunotherapy takes on rivals from Roche and BMS.

GSK's new CEO Walmsley paid 25% less than predecessor Witty

BMS appoints new science chief in fall-out from Opdivo setba...

Pfizer and Merck's diabetes contender looks to challenge Jar...

Blow for MSD as NICE rejects Keytruda in first line lung can...

Merck's failure casts gloom over remaining BACE Alzheimer's ...

Opdivo still clear immunotherapy leader despite Keytruda gai...

GBL joins CVC in €10.7bn takeover bid for Recordati

Discover a new era of healthcare panel engagement: Grounded ...

Merck &amp; Co

Editor's Picks

Merck & Co